Oncology Views & Analysis

Views & Analysis

Oncology

When it comes to myeloid malignancies such as acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS), treatment progress has been slow.

Oncology

At ESMO 2025, pharmaphorum spoke with Dr Ebrahim Delpassand, CEO of RadioMedix.

Oncology

At ESMO 2025, pharmaphorum had the pleasure of speaking with Michael Lahn, Chief Medical Officer at iOnctura.

Oncology

At ESMO 2025 in Berlin, pharmaphorum spoke with Jo Feng, president of Hengrui Pharma.

Oncology

As ESMO 2025 came to a close last month, pharmaphorum had the pleasure of catching up with Dr Sandeep Reddy, Chief Medical Officer at ImmunityBio.

Oncology

At ESMO 2025 in Berlin, pharmaphorum spoke with Tadaaki Taniguchi, Chief Research & Development Officer at Astellas.